Figure 11.

Summary of the work. Resveratrol-like compounds from our in-house library were first screened in silico to predict their ability to activate SIRT1 enzyme and bioavailability. Then, six selected compounds were tested in vitro to assess the potential activation of isolated SIRT1 enzyme. The best SIRT1 activator (compound 3d) underwent pharmacological investigation in human endothelial cells (HUVECs). In this final set of experiments, both the reference SIRT1 activator resveratrol and compound 3d prevented H₂O₂-induced cell viability reduction and ROS production, likely via activation of SIRT1.